# First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

> **NCT01568203** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AMG 579
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01568203
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Amgen decision (business)
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568203, "First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01568203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*